Trials / Completed
CompletedNCT00395434
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Mateon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combretastatin A4 Phosphate (CA4P) | |
| DRUG | Bevacizumab (Avastin) |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2006-11-02
- Last updated
- 2011-10-31
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00395434. Inclusion in this directory is not an endorsement.